Resources

Main Content

Newsletter Spring 2020

Mississippi Cancer Registry

March 2020 | Volume 15 Issue 1

MCR Educational Corner
Abstracting Resources
Upcoming Webinars
CTR Exam Schedule
Job Opening
Congratulations!
Upcoming Events
MCR Staff

Educational Corner 

Angel Davis, CTR, RHIT
MCR Data Quality Analyst – Trainer

 

HEAD & NECK TUMORS: Squamous Cell Carcinoma

Use of 8070 vs 8085/8086

To use histology 8085 or 8086 you must have a statement of “Squamous cell carcinoma HPV-positive” or “Squamous cell carcinoma HPV-negative”.

OR

Results from an HPV VIRAL DETECTION TEST to use 8085 or 8086.

The following tests identify the actual HPV virus:

  • Viral DNA by ISH test
  • Viral DNA by PCR test
  • ISH E6/E7 RNA test
  • PT-PCR E6/E7 RNA test

**DO NOT USE A p16 TEST TO CODE 8085 or 8086**

NOTE: If you have a statement that states “Squamous Cell Carcinoma HPV+” or “Squamous Cell Carcinoma HPV–” AND the pathology reports state p16+/p16– with no other testing completed, use histology 8070.

Reference: 2019-2020 NAACCR Webinar Series: Base of Tongue/ Head and Neck 2019

 

Calendar of Cancer Awareness Months

 

AJCC 8th Edition Helpful Tips

NX – Page 9 Note: The use of NX should be minimized. Page 15 Note: Clinical nodal category cN0 may be assigned based solely on physical examination. Imaging to assess regional lymph nodes is not required to assign clinical stage.

No designation of MX – The absence of any clinical history or physical findings suggestive of metastases in a patient who has not undergone any imaging is sufficient to assign the clinical M0 category (cM0).

No designation of pM0 – Biopsy or other pathological information is required to assign the pathological M1 category. Patients with a negative biopsy of a sus-pected metastatic site are classified as clinical M0 (cM0).

Incidental Tumor Finding – In the case where a cancerous tumor is found during another procedure or when cancer is not suspected, the clinical stage would be cT (blank) cN (blank) cM (blank) Stage 99.

pM1 – A patient may be staged as both clinical and pathological Stage IV if there is: (a) confirmatory microscopic evidence of a distant metastatic site during the diagnostic workup, which is categorized as pM1, and (b) T and N may be categorized only clinically. Example: cT3 cN1 pM1 clinical Stage IV and cT3 cN1 pM1 pathological Stage IV.

Unresectable tumor and assignment of pathological stage – If the highest T and N categories or the M1 category of the tumor are confirmed microscopically, even if a primary tumor technically cannot be removed or if it is unreasonable to remove it, the criteria for pathological staging are considered satisfied without total removal of the primary site.

(m) Suffix – Page 15: The (m) suffix applies to multiple invasive cancers. It is not applicable to multiple foci of in situ cancer or a mixed invasive and in situ cancer.

Reference - NCRA’s Webinar: Staging Tricky Tumor: Top Sites by Janet Vogel, CTR

 

MCRA Fall Educational Workshop

September 17, 2020

For more information, contact: Angel Davis, CTR – adavis6@umc.edu

Minimum Resources Required to Abstract

Grade

Beginning with cases diagnosed in 2018, grade information will be collected in three fields: Clinical Grade, Pathological Grade, and Post-Therapy Grade. Within the Grade Manual, you will find definitions for the three new grade data items, coding instructions, and the site/histology specific grade tables. The Grade manual is available at https://www.naaccr.org/SSDI/Grade-Manual.pdf?v=1527859766.

Summary Stage 2018

The 2018 version of Summary Stage applies to every site and/or histology combination, including lymphomas and leukemias. Summary Stage uses all information available in the medical record; in other words, it is a combination of the most precise clinical and pathological documentation of the extent of disease. The Summary Stage 2018 manual is available at https://seer.cancer.gov/tools/ssm/.

2018 Solid Tumor Coding Manual

Use the 2018 Solid Tumor coding rules to determine the number of primaries to abstract and the histology to code for cases diagnosed 2018 and forward. The Solid Tumor coding rules replace the 2007 Multiple Primary and Histology (MP/H) Rules. The manual is available at https://seer.cancer.gov/tools/solidtumor/. The change log contains updates made to the FINAL module sections. This does not include changes made to the drafts.

CoC 2018 STORE Manual

The STORE Manual has replaced the FORDS Manual. The STORE is now available at https://www.facs.org/quality-programs/cancer/ncdb/registrymanuals/cocmanuals.

Site Specific Data Items (SSDI)

Site Specific Data Items (SSDI) are similar to the Site Specific Factors (SSF) collected with Collaborative Stage. These data items are specific to certain site/histology combinations. For example, the SSDIs for breast will be used to collect information such as estrogen receptor status, progesterone receptor status, Her2 status, Nottingham grade, and additional information related to primary tumors of the breast. The information collected in these data items are specific to breast. The SSDI manual is available at https://apps.naaccr.org/ssdi/list/.

SEER Hematopoietic and Lymphoid Neoplasm Database

This provides data collection rules for hematopoietic and lymphoid neoplasms for 2010+. The SEER Hematopoietic and Lymphoid Neoplasm manual is available at https://seer.cancer.gov/tools/heme/Hematopoietic_Instructions_and_Rules.pdf.

AJCC Cancer Staging Manual

Cases with a diagnosis date of 01/01/2018 and forward should be staged using the AJCC 8th Edition Cancer Staging Manual. The 3rd printing 2018 Edition is now available.

Upcoming Webinars

Cancer Registry and Surveillance Webinar Series

4/2/20 - Melanoma

  • Denise Harrison, CTR and Louanne Currence, CTR

5/7/20 - Central Nervous System

  • Denise Harrison, CTR and Louanne Currence, CTR

6/11/20 - Esophagus

  • Tonya Brandenburg, CTR Kentucky Cancer Registry

For more information, contact: Angel Davis, CTR, RHIT — adavis6@umc.edu

https://www.naaccr.org/

CTR Exam 2020

Testing Dates and Deadlines

  • March 6 - March 27, 2020; application deadline: January 31, 2020
  • June 26 - July 17, 2020; application deadline: May 29, 2020
  • October 16 - November 6, 2020; application deadline: September 11, 2020

For more information, visit: http://www.ctrexam.org/

Job Openings

North Mississippi Medical Center has a CTR position available.

Anyone interested can apply at: http://apps.nmhs.net/employment/browse_jobs2.asp

Candidates will need to select Oncology Service Line (department) and Tupelo (location).

Congratulations!

G.V. (SONNY) Montgomery VA Medical Center welcomes Angela L. Brooks, RHIT, CTR as their new Cancer Registrar.

Upcoming Events

Cancer Registrars: 2020 Vision for the Future

National Cancer Registrars Week

April 6-10, 2020

 

NCRA's 46th Annual Educational Conference

20/20 Vision

Innovation | Education | Improving Cancer Data

September 20–23, 2020

Disney’s Coronado Springs Resort

Lake Buena Vista, FL

For more information, visit: https://ncra-usa.org/ 

 

Cancer Surveillance: Keystone of Progress

June 21-26

Philadelphia, PA

MCR Staff

Director UMMC & MCR: Deirdre Rogers, dbrogers@umc.edu 

MCR Manager: La'Tawnya Roby, ldroby@umc.edu

Clinical Systems Analyst-Intermediate: Tresheena Boyd, tboyd@umc.edu

Data Quality Analyst-Trainer: Angel Davis, adavis6@umc.edu

Data Quality Analyst-Auditor: Vacant

Electronic Data Source Coordinator: Lisa Hamel, lhamel@umc.edu

Cancer Registrars:

Administrative Assistant III: Ophelia Spencer, ospencer@umc.edu

University of Misissippi Medical Center
Mississippi Cancer Registry
2500 North State Street
Jackson, MS 39216
Phone:601-815-5482 | Fax:601-815-5483
We acknowledge the Centers for Disease Control